Open AccessInitial Experience With Conivaptan Use in Critically Ill Infants With Cardiac Disease
Author(s) -
Ryan Jones,
Surender Rajasekaran,
Mark Rayburn,
Joseph D. Tobias,
Robert M. Kelsey,
Glenn T. Wetzel,
Antonio G. Cabrera
Publication year - 2012
Publication title -
the journal of pediatric pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.456
H-Index - 15
eISSN - 2331-348X
pISSN - 1551-6776
DOI - 10.5863/1551-6776-17.1.78
Subject(s) - medicine , hyponatremia , diuresis , natriuresis , free water clearance , endocrinology , blood urea nitrogen , renal function , creatinine , sodium bicarbonate , chemistry
Arginine vasopressin (AVP) is the primary regulator of free water retention through its interactions with the AVP type 2 receptor (V(2)). As opposed to the natriuresis and diuresis that occur with loop and thiazide diuretics, conivaptan is an AVP V(1A)/V(2) receptor antagonist, which enhances free water excretion while minimizing sodium loss. We report our preliminary experience with conivaptan to promote diuresis in infants with functional or structural cardiac disease.